SCHEMBL1650848

SCHEMBL1650848

O=c1nc2cccnc2nc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAUR Q03405 1/20 0.47
ALDH1A1 P00352 4/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
HIF1A Q16665 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
F7 P08709 1/20 0.41
F3 P13726 1/20 0.41
TOP2A P11388 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
DHODH Q02127 1/20 0.40
CYP3A4 P08684 1/20 0.40
HCAR2 Q8TDS4 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5336924 0.98 PLAUR (0.46) PLAURALDH1A1TSHRCYP2C19NPC1
SCHEMBL8967704 0.87 CYP3A4 (0.46) PLAURALDH1A1TSHRCYP2C19NPC1
SCHEMBL2693525 0.87 HCAR2 (0.42) PLAURALDH1A1TSHRCYP2C19LMNA
SCHEMBL28915934 0.78 MAPT (0.55) ALDH1A1TSHRNPC1GAALMNA
Phenazine SCHEMBL19970688 0.78 MAPT (0.55) ALDH1A1TSHRNPC1GAALMNA
SCHEMBL2360699 0.78 PLAUR (0.59) PLAURALDH1A1TSHRRAB9AGAA
SCHEMBL22589760 0.77 PLAUR (0.47) PLAURALDH1A1TSHRCYP2C19GAA
Hydrochloric Acid SCHEMBL22748626 0.76 PLAUR (0.57) PLAURALDH1A1TSHRNPC1RAB9A
SCHEMBL9169312 0.74 METAP1 (0.40) ALDH1A1NPC1RAB9AGAALMNA
SCHEMBL28486850 0.73 ALDH1A1 (0.48) ALDH1A1TSHRCYP2C19NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023190663-A1 HIGH-PURITY COMPOUND PRODUCTION METHOD AND PURIFICATION METHOD 参天製薬株式会社 2023-10-05 WO claimed
EP-1590355-A1 NOVEL TRICYCLIC AZEPINE DERIVATIVES, METHOD FOR PRODUCTION THEROF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME LES LABORATOIRES SERVIER (FR) 2005-11-02 EP claimed
WO-2004069843-A1 NOVEL TRICYCLIC AZEPINE DERIVATIVES, METHOD FOR PRODUCTION THEROF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME LES LABORATOIRES SERVIER (FR) 2004-08-19 WO claimed
EP-0634932-A1 METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE MAMMALIAN EYE BY ADMINISTRATION OF MUSCARINIC ANTAGONISTS ALLERGAN, INC. (US) 1995-01-25 EP claimed
WO-1993018772-A1 METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE MAMMALIAN EYE BY ADMINISTRATION OF MUSCARINIC ANTAGONISTS ALLERGAN, INC. (US) 1993-09-30 WO claimed
EP-0254955-B1 Substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing these compounds Dr. Karl Thomae GmbH (DE) 1992-05-27 EP claimed
EP-0254955-A2 Substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing these compounds Dr. Karl Thomae GmbH (DE) 1988-02-03 EP claimed
JP-1193225-A None JP disclosed
US-12156868-B2 Formulations of pilocarpine and brimonidine compounds and related methods SOMERSET THERAPEUTICS, LLC (US) 2024-12-03 US disclosed
US-11857538-B2 Stable pilocarpine formulations with modified buffer characteristics and related methods SOMERSET THERAPEUTICS, LLC (US) 2024-01-02 US disclosed
US-11857539-B2 Gel ophthalmic formulations of pilocarpine and brimonidine compounds and related methods SOMERSET THERAPEUTICS, LLC (US) 2024-01-02 US disclosed
WO-2023190653-A1 STERILIZATION METHOD OF PHARMACEUTICAL PREPARATION AND PACKAGING 参天製薬株式会社 2023-10-05 WO disclosed
WO-2023190663-A1 HIGH-PURITY COMPOUND PRODUCTION METHOD AND PURIFICATION METHOD 参天製薬株式会社 2023-10-05 WO disclosed
JP-H01193225-A ANTIMUSCARINIC AGENT CONTAINING AROMATIC COMPOUND AS ACTIVE COMPONENT DOMPE FARMACEUT SPA 1989-08-03 JP disclosed
EP-0312895-A2 Condensed diazepinones, process for their preparation and medicament containing them Dr. Karl Thomae GmbH (DE) 1989-04-26 EP disclosed
EP-0288201-A1 Process for the preparation of benzodiazepines A.H. ROBINS COMPANY, INCORPORATED (US) 1988-10-26 EP disclosed
US-4749788-A Process for the preparation of aryl-pyrido(1,4) benzodiazepines A. H. ROBINS COMPANY, INCORPORATED (US) 1988-06-07 US disclosed
EP-0254955-A2 Substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing these compounds Dr. Karl Thomae GmbH (DE) 1988-02-03 EP disclosed
EP-0254955-A2 Substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing these compounds Dr. Karl Thomae GmbH (DE) 1988-02-03 EP disclosed
EP-0254955-A2 Substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing these compounds Dr. Karl Thomae GmbH (DE) 1988-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11857538-B2 Stable pilocarpine formulations with modified buffer characteristics and related methods PDE4B, PDE6A, PDE10A PLAUR 1484/4885ALDH1A1 4157/4885TSHR 1719/4885
US-11857539-B2 Gel ophthalmic formulations of pilocarpine and brimonidine compounds and related methods PDE6C, PDE6D, PDE6H PLAUR 2265/4885ALDH1A1 3996/4885TSHR 1850/4885
US-12156868-B2 Formulations of pilocarpine and brimonidine compounds and related methods PDE6C, PDE6H, SLC6A11 PLAUR 2076/4885ALDH1A1 3717/4885TSHR 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.